Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule cancer therapies. Its pipeline is centered on azenosertib and other compounds licensed from third parties, with development activities organized through its wholly owned subsidiaries.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates in preclinical and clinical development for cancer indications.
Upfront, milestone, or other revenue from licensing intellectual property to partners.
Customers
Zentalis does not sell approved medicines directly to patients or hospitals; its counterparties are primarily pharmaceutical and biotechnology partners, licensors, and potential collaborators. The company’s future commercial customers would be oncology prescribers and healthcare systems if its product candidates reach approval, but today the business is built around development-stage partnering and licensing.
Pharmaceutical or biotech counterparties that fund, co-develop, or commercialize pipeline assets.
Owners of licensed technology and patents, including parties behind the Recurium agreement.
Oncologists, hospitals, and cancer centers that would use approved products if development succeeds.
Investigators, CROs, and trial sites that support patient enrollment and study execution.
Strategy
Zentalis’ strategy is to advance azenosertib and other licensed oncology assets through clinical development and, if successful, toward regulatory approval and commercialization. The company also uses collaborations and licensing to extend its pipeline and to access capital, expertise, and commercialization pathways.
The lead program is the core value driver and the main path to regulatory approval.
Collaborations can provide capital, development support, and commercialization reach.
A successful asset will require manufacturing, regulatory, and commercial infrastructure.
Geography
Zentalis is headquartered in the United States and operates as a U.S.-based development company, while its licensing rights are described as worldwide. Its business is therefore geographically global in intellectual property scope, but operationally concentrated in the U.S. and in the clinical trial geographies used for oncology development.
Risks
Zentalis faces the typical risks of a clinical-stage biopharmaceutical company: no approved products, heavy dependence on successful trials, and uncertainty around regulatory approval and commercialization. It also depends on external financing and licensed intellectual property, while competing against larger oncology companies with greater resources and more advanced pipelines.
- Clinical development failureImpact: CriticalLikelihood: Medium
The company’s value depends on successful trial outcomes for azenosertib and other candidates.
Exposure: Azenosertib and pipeline assets
- Financing riskImpact: HighLikelihood: High
The company has no product-sales revenue and must fund R&D and trials through external capital.
Exposure: Operating runway and development pace
- Regulatory approval riskImpact: HighLikelihood: Medium
Drug candidates must satisfy FDA and other regulators before commercialization.
Exposure: Late-stage oncology programs
- Competition from larger oncology developersImpact: HighLikelihood: Medium
Well-funded peers may advance similar mechanisms or approved therapies faster.
Exposure: Targeted cancer indications
- License and IP dependencyImpact: MediumLikelihood: Low
Key assets are based on third-party licensed intellectual property with contractual obligations.
Exposure: Recurium agreement and related rights
Accounting
Judgemental itemsCollaboration and license payments may be recognized at different times depending on contract terms and performance obligations.
Impact: Can create quarter-to-quarter volatility in reported revenue
Clinical trial and development spending is the dominant expense category and is highly program-dependent.
Impact: Drives operating loss and reflects pipeline progress
Changes in the value of held equity investments flow through other income/expense.
Impact: Can materially move non-operating results
Tax assets depend on future taxable income and realizability assumptions.
Impact: Affects deferred tax asset recognition and tax expense
One-time termination benefits require estimation of severance and related costs.
Impact: Affects operating expenses and comparability across periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Zenas BioPharma, Inc.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Nuvalent, Inc.
Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Last updated: 24/09/2026